These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12956760)

  • 1. Induction of antitumour immunity using survivin peptide-pulsed dendritic cells in a murine lymphoma model.
    Siegel S; Wagner A; Schmitz N; Zeis M
    Br J Haematol; 2003 Sep; 122(6):911-4. PubMed ID: 12956760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells.
    Zeis M; Siegel S; Wagner A; Schmitz M; Marget M; Kühl-Burmeister R; Adamzik I; Kabelitz D; Dreger P; Schmitz N; Heiser A
    J Immunol; 2003 Jun; 170(11):5391-7. PubMed ID: 12759413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma.
    Ciesielski MJ; Kozbor D; Castanaro CA; Barone TA; Fenstermaker RA
    Cancer Immunol Immunother; 2008 Dec; 57(12):1827-35. PubMed ID: 18438666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Experimental study on activating antileukemic T cells by vaccination with dendritic cells pulsed with survivin].
    Zhang XH; Xia LH; Liu ZP; Wei WN; Hu Y; Song SJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Feb; 11(1):66-9. PubMed ID: 12667293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and characterization of survivin-derived H-2Kb-restricted CTL epitopes.
    Hofmann UB; Voigt H; Andersen MH; Straten PT; Becker JC; Eggert AO
    Eur J Immunol; 2009 May; 39(5):1419-24. PubMed ID: 19337999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors.
    Nagaraj S; Pisarev V; Kinarsky L; Sherman S; Muro-Cacho C; Altieri DC; Gabrilovich DI
    J Immunother; 2007; 30(2):169-79. PubMed ID: 17471164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor cytotoxic T-cell response induced by a survivin peptide mimic.
    Ciesielski MJ; Ahluwalia MS; Munich SA; Orton M; Barone T; Chanan-Khan A; Fenstermaker RA
    Cancer Immunol Immunother; 2010 Aug; 59(8):1211-21. PubMed ID: 20422411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.
    Hirohashi Y; Torigoe T; Maeda A; Nabeta Y; Kamiguchi K; Sato T; Yoda J; Ikeda H; Hirata K; Yamanaka N; Sato N
    Clin Cancer Res; 2002 Jun; 8(6):1731-9. PubMed ID: 12060610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas.
    Ciesielski MJ; Apfel L; Barone TA; Castro CA; Weiss TC; Fenstermaker RA
    Cancer Immunol Immunother; 2006 Dec; 55(12):1491-503. PubMed ID: 16485128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced induction of anti-tumor immunity in human and mouse by dendritic cells pulsed with recombinant TAT fused human survivin protein.
    Cho HI; Kim EK; Park SY; Lee SK; Hong YK; Kim TG
    Cancer Lett; 2007 Dec; 258(2):189-98. PubMed ID: 17931768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope.
    Armstrong AC; Dermime S; Allinson CG; Bhattacharyya T; Mulryan K; Gonzalez KR; Stern PL; Hawkins RE
    J Immunol; 2002 Apr; 168(8):3983-91. PubMed ID: 11937555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monocyte-derived dendritic cells generated after a short-term culture with IFN-alpha and granulocyte-macrophage colony-stimulating factor stimulate a potent Epstein-Barr virus-specific CD8+ T cell response.
    Santodonato L; D'Agostino G; Nisini R; Mariotti S; Monque DM; Spada M; Lattanzi L; Perrone MP; Andreotti M; Belardelli F; Ferrantini M
    J Immunol; 2003 May; 170(10):5195-202. PubMed ID: 12734367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-specific peptide-based vaccines containing the conformationally biased, response-selective C5a agonists EP54 and EP67 protect against aggressive large B cell lymphoma in a syngeneic murine model.
    Kollessery G; Nordgren TM; Mittal AK; Joshi SS; Sanderson SD
    Vaccine; 2011 Aug; 29(35):5904-10. PubMed ID: 21723901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies.
    Siegel S; Wagner A; Kabelitz D; Marget M; Coggin J; Barsoum A; Rohrer J; Schmitz N; Zeis M
    Blood; 2003 Dec; 102(13):4416-23. PubMed ID: 12869512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cell targeting of survivin protein in a xenogeneic form elicits strong CD4+ T cell immunity to mouse survivin.
    Charalambous A; Oks M; Nchinda G; Yamazaki S; Steinman RM
    J Immunol; 2006 Dec; 177(12):8410-21. PubMed ID: 17142738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides.
    Schmitz M; Diestelkoetter P; Weigle B; Schmachtenberg F; Stevanovic S; Ockert D; Rammensee HG; Rieber EP
    Cancer Res; 2000 Sep; 60(17):4845-9. PubMed ID: 10987296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine.
    Ohtake J; Ohkuri T; Togashi Y; Kitamura H; Okuno K; Nishimura T
    Immunol Lett; 2014 Sep; 161(1):20-30. PubMed ID: 24794408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel mimovirus vaccine containing survivin epitope with adjuvant IL-15 induces long-lasting cellular immunity and high antitumor efficiency.
    Yang Z; Wang L; Wang H; Shang X; Niu W; Li J; Wu Y
    Mol Immunol; 2008 Mar; 45(6):1674-81. PubMed ID: 18035418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.
    Bellone M; Cantarella D; Castiglioni P; Crosti MC; Ronchetti A; Moro M; Garancini MP; Casorati G; Dellabona P
    J Immunol; 2000 Sep; 165(5):2651-6. PubMed ID: 10946294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.